S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:TNDM

Tandem Diabetes Care (TNDM) Price Target & Analyst Ratings

$21.99
+1.22 (+5.87%)
(As of 10/2/2023 ET)
Compare
Today's Range
$20.60
$22.28
50-Day Range
$19.33
$36.22
52-Week Range
$19.11
$58.82
Volume
1.57 million shs
Average Volume
1.30 million shs
Market Capitalization
$1.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.80

Tandem Diabetes Care Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$44.27
101.30% Upside
High Prediction$62.00
Average Prediction$44.27
Low Prediction$23.00
TypeCurrent
10/2/22 to 10/2/23
1 Month Ago
9/2/22 to 9/2/23
3 Months Ago
7/4/22 to 7/4/23
1 Year Ago
10/2/21 to 10/2/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$44.27$46.80$50.71$103.36
Predicted Upside101.30% Upside27.14% Upside26.10% Upside33.46% Upside
Get Tandem Diabetes Care Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.


TNDM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TNDM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Tandem Diabetes Care Stock vs. The Competition

TypeTandem Diabetes CareMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.65
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside115.70% Upside605.70% Upside21.71% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$31.00 ➝ $23.00+5.80%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$47.00 ➝ $45.00+116.66%
8/21/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$33.00 ➝ $32.00+9.70%
8/4/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$71.00 ➝ $62.00+85.57%
8/4/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$52.00 ➝ $34.00+2.87%
8/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $30.00-7.44%
6/13/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$74.00 ➝ $50.00+93.12%
5/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$45.00 ➝ $33.00-12.02%
5/4/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $40.00+9.47%
4/24/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/28/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$45.00+11.83%
2/23/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$70.00 ➝ $50.00+24.84%
2/23/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$61.00 ➝ $52.00+29.84%
1/26/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
11/3/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$107.00 ➝ $61.00+64.15%
11/3/2022Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$150.00 ➝ $60.00+16.87%
(Data available from 10/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TNDM Price Target - Frequently Asked Questions

What is Tandem Diabetes Care's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Tandem Diabetes Care stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for TNDM. The average twelve-month price prediction for Tandem Diabetes Care is $44.27 with a high price target of $62.00 and a low price target of $23.00. Learn more on TNDM's analyst rating history.

Do Wall Street analysts like Tandem Diabetes Care more than its competitors?

Analysts like Tandem Diabetes Care less than other Medical companies. The consensus rating for Tandem Diabetes Care is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how TNDM compares to other companies.

Is Tandem Diabetes Care being downgraded by Wall Street analysts?

Over the previous 90 days, Tandem Diabetes Care's stock had 1 downgrade by analysts.

Does Tandem Diabetes Care's stock price have much upside?

According to analysts, Tandem Diabetes Care's stock has a predicted upside of 30.95% based on their 12-month price targets.

What analysts cover Tandem Diabetes Care?

Tandem Diabetes Care has been rated by Barclays, Citigroup, Jefferies Financial Group, Robert W. Baird, TD Cowen, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:TNDM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -